SEQUENT Stock Overview
Operates in the veterinary healthcare business in Europe, Asia, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Sequent Scientific Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹180.09 |
52 Week High | ₹240.70 |
52 Week Low | ₹92.05 |
Beta | 1.03 |
1 Month Change | 23.16% |
3 Month Change | 12.90% |
1 Year Change | 63.50% |
3 Year Change | 67.53% |
5 Year Change | 113.38% |
Change since IPO | 0.38% |
Recent News & Updates
What Sequent Scientific Limited's (NSE:SEQUENT) 27% Share Price Gain Is Not Telling You
May 15Sequent Scientific Limited's (NSE:SEQUENT) 27% Price Boost Is Out Of Tune With Revenues
May 15Recent updates
What Sequent Scientific Limited's (NSE:SEQUENT) 27% Share Price Gain Is Not Telling You
May 15Sequent Scientific Limited's (NSE:SEQUENT) 27% Price Boost Is Out Of Tune With Revenues
May 15We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt
Jan 28We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt
Sep 27What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You
Sep 05Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)
Apr 05Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet
Mar 10Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?
Jan 31How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?
Jan 17Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?
Jan 05What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?
Dec 24Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?
Dec 12Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly
Nov 22Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)
Nov 10Shareholder Returns
SEQUENT | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 2.1% | -0.07% | -0.3% |
1Y | 63.5% | 12.7% | 1.3% |
Return vs Industry: SEQUENT exceeded the Indian Pharmaceuticals industry which returned 13% over the past year.
Return vs Market: SEQUENT exceeded the Indian Market which returned 2.7% over the past year.
Price Volatility
SEQUENT volatility | |
---|---|
SEQUENT Average Weekly Movement | 8.0% |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 7.0% |
10% most volatile stocks in IN Market | 9.6% |
10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: SEQUENT has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SEQUENT's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1985 | 1,195 | Rajaram Narayanan | www.sequent.in |
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products.
Sequent Scientific Limited Fundamentals Summary
SEQUENT fundamental statistics | |
---|---|
Market cap | ₹44.96b |
Earnings (TTM) | ₹218.80m |
Revenue (TTM) | ₹15.66b |
Is SEQUENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SEQUENT income statement (TTM) | |
---|---|
Revenue | ₹15.66b |
Cost of Revenue | ₹8.12b |
Gross Profit | ₹7.54b |
Other Expenses | ₹7.32b |
Earnings | ₹218.80m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | 0.88 |
Gross Margin | 48.16% |
Net Profit Margin | 1.40% |
Debt/Equity Ratio | 57.9% |
How did SEQUENT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/22 03:34 |
End of Day Share Price | 2025/05/22 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sequent Scientific Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nikhil Shetty | BP Wealth Management Private Limited |
null null | IIFL Wealth Management Ltd. |